Definitive Contract 75N93018C00037
Award Date
8/22/18
Potential Completion Date
9/27/22
Potential Value
$322K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Profectus Biosciences, Inc.
Ultimate Awardee
Not listed
NAICS Category
238990 - All Other Specialty Trade Contractors
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Baltimore, MD 21224, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Profectus Biosciences, Inc., a small business. The contract, with a potential value of $3,383,522.51, is for research and development in the biomedical field, specifically focused on applied research and exploratory development of vaccine technologies. The contract does not have a set-aside designation....
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Profectus Biosciences, Inc., a small business. The contract, valued at $4,214,664.98, is for the production of a pDNA vaccine expressing FLSC as part of the agency's Staged Vaccine Development program. The contract does not have a set-aside designation. The contract supports the development of novel vaccine...
This is a $600,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to develop an effective human immunodeficiency virus (HIV) vaccine using engineered nanoparticles loaded with messenger RNA (mRNA) targeted to antigen presenting cells. This contract is part of the Small Business Innovation Research (SBIR)...
Hafion Inc., a self-certified small disadvantaged and woman-owned small business, was awarded a $310,592 Firm Fixed Price Definitive Contract from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS NIH NIAID) under the HHS SBIR Program. The contract, which was set aside for small businesses, is for research and development services related to the development of protein:non-protein macromolecular adjuvants. The...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Neovaxsyn Inc., a minority-owned, self-certified small disadvantaged business based in Ames, Iowa. The $300,000.00 firm fixed-price contract is for research and development related to HIV/AIDS vaccines, including the use of nanoparticles to deliver vaccine components and...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, valued at $299,999, was awarded to Neovaxsyn Inc. to develop a protective HIV vaccine utilizing gold nanoparticles to elicit broadly neutralizing antibodies against the fusion peptide of HIV-1 GP41. The contract was awarded under the Small Business Innovation Research Program Phase I solicitation, which sought proposals for research...
This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
The prime contractor Molecular Express Inc. was awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract by the National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, the contractor will engineer novel HIV GP41 ectodomain antigens for incorporation into VESIVAX immunogenic formulations, in response to a solicitation seeking proposals aligned with NIH and CDC public health missions. This total small business...